News | December 16, 2025
Sanofi secures two breakthrough nods in China for rare blood disorders
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
The facility is dedicated to breakthrough innovations in laboratory instruments that detect infectious diseases, cancer, and blood disorders
Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Launches Thalassemia Bal Sewa Yojana portal and releases standard treatment guidelines for sickle cell anemia disease
The new center will focus on supporting the clinical trials clients who are developing cell and gene therapies
Thalassemia and Sickle Cell Society (TSCS) always stands forefront in providing blood transfusion free of cost for Thalassemia Blood disorders patients
Subscribe To Our Newsletter & Stay Updated
